On May 21, 2026, Simcere Zaiming announced that SIM0532, a pan-RAS-targeted investigational anti-tumor drug independently developed by the company, ha...

May 6, 2026, Simcere Zaiming announces today that SIM0613 for Injection, an LRRC15-targeting antibody-drug conjugate (ADC) independently developed by ...

April 8 2026, Simcere Zaiming announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for SIM0505, for the treat...

March 30, 2026 — Simcere Pharmaceutical Group Limited (2096.HK) announced that Phase III results from the RADIANT-AD study of rademikibart, an investi...